Erectile dysfunction (ED) is especially common in men with major depressive disorder (MDD). This study examined the extent to which risk factors for cardiovascular disease (CVD) and vascular endothelial dysfunction were associated with ED severity in MDD patients. The sample included 46 middle-aged [M (s.d.) ¼ 53 (7) 
Introduction
It is estimated that 34 million American men have some degree of erectile dysfunction (ED). 1 It is associated with subclinical cardiovascular disease (CVD), as well as CVD risk factors such as hypertension, hyperlipidemia and diabetes mellitus, [2] [3] [4] [5] [6] [7] and ED is increasingly viewed as a plausible surrogate marker for underlying CVD. 8, 9 The prevalence of ED appears to be higher among patients with multiple CVD risk factors 10 or significant CVD 11 as compared with healthy controls (e.g., 65 vs 22%). 11 Furthermore, ED in otherwise healthy men has been observed to be a potent predictor of incident CVD in large, observational studies. 12 For example, among 25 000 managed-care customers without known CVD, ED at baseline was associated with a twofold increase in the risk for a first myocardial infarction after adjusting for confounds. 13 Among 4200 men without CVD or ED who were followed up for up to 7 years, incident ED was associated with an increased risk of all cardiovascular events (hazard ratio (HR) ¼ 1.27), with an effect size comparable with family history of myocardial infarction (MI) (HR ¼ 1.36), smoking (HR ¼ 1.56) and the use of antihypertensive medication at baseline (HR ¼ 1.29).
14 It is therefore not surprising that medical providers have been encouraged to evaluate patients with ED for cardiovascular risk factors. 14 ED and CVD appear to share pathogenic mechanisms by which traditional CVD risk factors, such as cigarette smoking, diabetes, and obesity, result in a reduction in nitric oxide activity. 15, 16 Nitric oxide availability is critical both for vascular erectile function 17, 18 and for normal endothelial function, 15, 19 and reduced nitric oxide activity can result in vascular endothelial dysfunction and subsequent CVD. 19 Endothelial dysfunction is hypothesized to have a primary role in the pathogenesis of CVD, preceding the development of atherosclerotic plaque, and may therefore represent an important marker of risk in patients without clinically apparent vascular disease. 19 In several small-scale studies, vascular endothelial dysfunction, as measured by flow-mediated dilation (FMD), has been observed to correlate with ED severity, 20 and also to differentiate patients with ED from controls. 21, 22 ED also can be affected by psychological comorbidities, especially the presence of clinical depression. 5, 10, 23, 24 Decreased interest in sex and other pleasurable activities has long been recognized as a classic depressive symptom, 25 and epidemiological studies have observed positive correlations between ED and depression. 23 For example, among 1709 men from the Massachusetts Male Aging Study (MMAS), depression (Center for Epidemiologic Studies Depression Scale X16) was associated with 1.82 times greater risk for moderate or severe ED, after controlling for potential confounds. 24 Despite the significant data indicating that vascular disease and depression tend to occur in the same patients, the relationship between CVD risk factors and ED has yet to be studied among clinically depressed men.
We examined the relationship between CVD risk factors and vascular endothelial function in adult men with major depressive disorder. Data were obtained from baseline assessments of men enrolled in a clinical trial of exercise and depression that has been previously reported. 26 We hypothesized that, among this sample of clinically depressed, sedentary, middleaged and older men, greater levels of depression severity would be related to greater severity of ED, that CVD risk would predict ED severity independent of the effects of depression and that the relationship between CVD risk and ED would be explained by vascular endothelial dysfunction assessed by FMD.
Materials and methods
The sample consisted of 46 male participants of the SMILE-II study, a randomized clinical trial of exercise and anti-depressant medication in patients with major depression. 26 This study was approved by the Duke University Institutional Review Board. The Declaration of Helsinki protocols were followed and all study participants gave their written, informed consent. Briefly, participants were recruited between October 2000 and November 2005. Participants included sedentary adults with scores of X12 on the Beck Depression Inventory-II (BDI) 27 who met clinical diagnostic criteria for major depressive disorder 28 assessed using the Structured Clinical Interview for Depression (SCID). 29 Exclusion criteria included poorly controlled diabetes mellitus, inability to participate in regular exercise, medical exclusion to taking antidepressant medication, current participation in exercise, current use of antidepressant medication or diagnosis of bipolar disorder or psychotic depression. Psychological assessments were performed by clinicians blind to group assignment. Variables were measured as follows: ED ED was measured by response to a single-item on the five-item Arizona Sexual Experiences Scale (ASEX), 30 in which each item corresponds to a core element of sexual functioning (that is, sex drive, arousal, erection, orgasm and satisfaction). For the purposes of this study, participants responded to the question 'can you easily get and keep an erection?' Response options rage from 1 ¼ 'Extremely' to 6 ¼ 'Never.' In the original validation study, the ASEX was examined both as a series of single-time instruments and also as an overall measure of global sexual functioning. 30 Similar single-item measures of ED have been shown to be reliable, valid and sensitive to change.
12,31-33
Depression All patients were diagnosed with major depressive disorder based on a clinical interview administered by a trained clinical psychologist. 29 Depression severity was measured with the BDI, a self-report scale consisting of 21 items, each corresponding to a specific category of symptoms and attitudes. 27 The severity of each symptom is rated on a 4-point scale, and the total score is determined by adding the sum of the individual items. The BDI has been widely used as a measure of depression severity in studies of healthy adults and adults with CVD. 27 CVD risk CVD risk was quantified as the Framingham-based CVD risk calculation score 34 and body mass index (BMI). The Framingham risk score uses Cox proportional-hazards regression coefficients to calculate the estimated 10-year risk for any CVD event (that is, coronary heart disease, cerebrovascular events, peripheral artery disease, or heart failure) from sex (male/female), smoking (yes/no), diabetes (yes/no), and the natural logarithm of age, total cholesterol, high-density lipoprotein and systolic blood pressure (different coefficients are used depending on whether a patient is taking antihypertensive medication). The Framingham risk score algorithm was developed from a data set consisting of nearly 8500 Framingham study participants who were followed for 12 years. BMI also was included as a measure of CVD risk because, although it is not part of the Framingham risk algorithm, it is associated with CVD events, and it is also associated with ED. Data for the Framingham risk and BMI calculations (that is, height, weight, systolic blood pressure, diabetes diagnosis, current use of any medications and current smoking) were gathered from each participant by a study physician assistant. Lipid values were derived from fasting blood work, drawn and analyzed in an on sight, dedicated research laboratory.
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Endothelial function
Endothelial function was measured by FMD of the brachial artery, using standard procedures. 35 Longitudinal B-mode ultrasound images of the brachial artery, 4-6 cm proximal to the antecubital crease, were obtained using an Acuson Aspen (Mountain View, CA, USA) ultrasound platform with an 11-MHz linear array transducer. All images were obtained by the same sonographer (blinded to treatment), who had extensive experience with the FMD technique and who held the transducer manually. Images were obtained under the following conditions: (i) after 10 min of supine relaxation; (ii) during reactive hyperemia, induced following inflation for 5 min to supra-systolic pressure (B200 mm Hg) of a pneumatic occlusion cuff placed around the forearm, and (iii) after administration of 400 mg sublingual glyceryl trinitrate spray. End-diastolic images were stored to a magnetic-optical disk and arterial diameters were measured as the distance between the proximal and distal arterial wall intima-media interfaces using PC-based software (Brachial Analyzer Version 4.0, Medical Imaging Applications LLC, Iowa City, IA, USA).
Peak hyperemic flow was assessed by Doppler velocity measurement during the first 10-s postdeflation of the occlusion cuff, and hyperemic flow response was defined as percentage change in flow relative to resting baseline. Peak FMD response was assessed from 10 to 120 s post-deflation of the cuff, with peak arterial diameter quantified using polynomial curve fitting, and FMD was defined as the maximum percentage change in arterial diameter relative to resting baseline. FMD has been shown to correlate with CVD risk factors 36 and is predictive of future CVD events. 37 Data analysis A bivariate correlation matrix was generated to examine relationships between depression severity, CVD risk, endothelial function and erectile function. The relationship between self-reported erectile function and CVD risk was modeled with a regression analysis in which the Framingham risk score served as the dependent variable and ASEX score served as the predictor. The primary analysis consisted of a hierarchical forced entry multiple-regression analysis in which the dependent variable was ASEX score and the a priori selected predictors were BDI, BMI, Framingham risk score and FMD, entered in that order. As age is a component of the Framingham risk score calculation, it was not included as a separate predictor in our primary analyses. All analyses were carried out with SAS v 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Demographics
The sample consisted of 46 middle-aged (53.4 years old), moderately depressed (BDI ¼ 27.8) men, who generally were Caucasian (73.9%), overweight (BMI ¼ 29.8) and married (60%) (see Table 1 ). The average ASEX score (on the 1-6 scale) was 3.2, indicating self-reported ED severity between 'somewhat easily' and 'somewhat difficult.' A total of 35% of the sample had been diagnosed with hypertension, 11% were diabetic and 13% were smokers; 30% were taking a medication that is known to possibly interfere with erectile function (typically a b-blocker). Half of the men in this study were non-smokers, non-diabetics, normotensive and were not taking medications with ED as a known side Correlation analyses A bivariate correlation matrix was constructed to examine the two-way relationships between all key variables (see Table 2 ). ED was not associated with depression severity (r ¼ 0.00, P ¼ 0.99), and was modestly and nonsignificantly related to BMI (r ¼ 0.19, P ¼ 0.20). In contrast, greater ED was associated with higher CVD risk (r ¼ 0.42, P ¼ 0.004) and was inversely correlated with FMD (r ¼ À0.49, P ¼ 0.0006). Age was strongly associated with the Framingham risk score (r ¼ 0.60, Po0.0001), and also with ED (r ¼ 0.43, P ¼ 0.003).
ED and CVD Risk
The relationship between self-reported erectile function and CVD risk was modeled with a regression analysis, in which the Framingham risk score served as the dependent variable and ASEX score served as the predictor. Self-reported ED severity was associated with greater Framingham risk score (b ¼ 0.42, P ¼ 0.004); specifically, a 1-point increase in self-reported ED was associated with a 3.2% increase in estimated CVD risk over the next decade.
Depression, CVD risk, endothelial function and ED
The contributions of depression severity, Framingham risk score and vascular endothelial function were examined with a hierarchical forced entry multiple-regression analysis, in which the dependent variable was ASEX score and the predictors were BDI, BMI, Framingham risk score and FMD, entered in that order (see Table 3 ). BDI did not predict self-reported ED (b ¼ 0.00, P ¼ 0.997). When BMI was added to the model, it also did not predict ED (b ¼ 0.19; P ¼ 21). However, when the Framingham risk score was added to the model, it was a significant independent predictor of ED (b ¼ 0.41, P ¼ 0.008). Furthermore, when FMD was added to the model, it was a significant predictor of ED (b ¼ À0.38, P ¼ 0.01), and the effect of CVD risk on ED was partially attenuated (b ¼ 0.27, P ¼ 0.08). Taken together, these results indicate that CVD risk was a significant contributor to self-reported ED and that this relationship was partially mediated by endothelial function.
Secondary analyses
We conducted a number of sensitivity analyses. First, we examined the role of baseline brachial artery diameter in the prediction of self-reported ED severity and with respect to the association between CVD risk and ED. When baseline brachial artery diameter was included in the full model, it was not a significant predictor of ED (b ¼ 0.08, P ¼ 0.61), and it had little effect on the contribution of the
In a second sensitivity analysis, we evaluated the unique effects of endothelial-mediated vasodilatation by re-estimating the full model replacing FMD with nitroclycerine-mediated vasodilation (NGT, an index of endothelial-independent vasodilation). When NGT was included in the final model instead of FMD, NGT was not a significant predictor of ED (b ¼ À0.30, P ¼ 0.06), and the inclusion of NGT did not attenuate the relationship between CVD risk and ED (b ¼ 0.39, P ¼ 0.009). When both NGT and FMD were included in the model, FMD was a significant predictor of ED (b ¼ À0.31, P ¼ 0.05), whereas NGT was not (b ¼ À0.15, P ¼ 0.35).
Finally, we examined the contribution of FMD to self-reported ED among non-diabetics and among participants who were not taking antihypertensives. The association between FMD and ED remained essentially unchanged excluding participants with diabetes (n ¼ 41, b ¼ À0.36, P ¼ 0.03), and excluding men who were taking anti-hypertensive medication (n ¼ 32, b ¼ À0.42, P ¼ 0.02).
Discussion
Ten-year CVD risk as estimated by the Framingham risk score was associated with greater self-reported ED severity. In addition, impaired endothelial function also was associated with greater selfreported ED, and accounted for a significant proportion of the effects of CVD risk on ED. These results are consistent with the hypothesis that ED is a marker of CVD risk, and they contribute further evidence to the body of data suggesting that endothelial dysfunction may underlie the relationship between CVD risk and ED. In addition, these results extend previous study among clinically depressed men by showing that the observed association between depression and ED may be partially attributable to underlying CVD. In secondary analyses, the effect of FMD on ED was similar, regardless of whether patients with hypertension or diabetes were included in the analyses. Furthermore, although the inclusion of FMD in the model attenuated the relationship between cardiovascular risk and ED, the inclusion of NGT did not. Taken together, these secondary analyses reinforce the robustness of the primary findings, and lend additional support to the hypothesis that cardiovascular risk and ED are linked at the level of the endothelium.
Neither depression severity nor BMI contributed to self-reported ED in this study. This stands in contrast to our hypotheses, as well as previous studies of patients with ED. 3, 5 The lack of association between depression severity and ED in this sample of clinically depressed men may indicate that it is the categorical presence of depression, and not the severity of depression, that contributes to ED. If this is true, then the correlation between depression and ED should only be observable among samples that include both depressed and non-depressed men [for example, Grover et al. 3 and Feldman et al.
10
], and it should not be observable in studies such as ours, which did not include non-depressed controls. Although the association between BMI and ED did not reach statistical significance, the effect sizes associated with the relationship between BMI and ED (r ¼ 0.19 in the correlation analyses, and b ¼ 0.19 in the regression analyses) suggest that our sample size may simply have been too small to detect the impact of BMI on ED.
Limitations
Our study is limited by our relatively small sample size. Inclusion of only 46 subjects is adequate for an exploratory analysis with four predictors, 38 but a larger sample would greatly increase our confidence in the generalizability of the size of our b-weight estimates, as well as reduce the likelihood of type II error as we noted with respect to the relationship of BMI and ED. As all of our participants were depressed, the relationship of ED and depression severity may have been affected by this limited range. Inclusion of non-depressed individuals is suggested for future studies. These findings also may be limited by our use of a single-item measure of self-reported erectile function. The International Index of Erectile Function (IIEF) is a multi-item selfreport measure that has become the 'gold standard' of efficacy assessment in ED research. 39 We encourage researchers seeking to confirm the current findings to administer the IIEF along with or instead of the ASEX. Finally, the current findings may not generalize to men who are younger than 40 years, non-obese and/ or physically active.
Conclusions
Findings from this study indicate that severity of ED among clinically depressed men is associated with graded increases in cardiovascular risk and impaired endothelial function. These findings should encourage medical and mental health providers to avoid attributing ED to clinical depression simply because a patient is clinically depressed. Rather, medical and mental health providers should consider underlying CVD in the pathogenesis of ED when treating men with depression. 
